Grants & Programs

MIATA Project

The Minimal Information About T cell Assays (MIATA) Project was launched in 2009 by a collaborative group including the CRI Cancer Immunotherapy Consortium (CIC), the Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP), and scientists at Stanford University. MIATA represented the first systematic effort to establish a framework for reporting immune monitoring data from T cell assays used in clinical trials, with the goal of fostering reliability of data to facilitate meaningful interpretation, comparison, and meta-analysis across clinical trials. MIATA aimed to achieve broad consensus on which T cell assay parameters should be reported in scientific publications and to propose a mechanism for reporting these in a systematic manner.

Since its inception, the project has gone through an intense vetting process including two public consultation periods and two public workshops. Integrating feedback from more than 120 contributors from around the world, the MIATA guidelines were finalized in 2012 and announced in the commentary, "T Cell Assays and MIATA: The Essential Minimum for Maximum Impact," published in Immunity in July 2012.

The new guidelines promise to help accelerate progress in cancer immunotherapy development by making data interpretation and comparison easier for investigators and regulatory agencies.

MIATA Tools and Resources

  • Finalized MIATA modules, published in Immunity and located on the MIATA website

Related Publications

  • Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring, Onco-immunology, December 2012. Access online
  • Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond, Cancer Immunology, Immunotherapy, Cancer Immunology, Immunotherapy, January 2011. Access online
  • Announcement of MIATA, Immunity, October 2009. Access online


Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at or (212) 688-7515.